CN103068393A - 用于抑制过渡型内质网atp酶的方法和组合物 - Google Patents

用于抑制过渡型内质网atp酶的方法和组合物 Download PDF

Info

Publication number
CN103068393A
CN103068393A CN201180026946XA CN201180026946A CN103068393A CN 103068393 A CN103068393 A CN 103068393A CN 201180026946X A CN201180026946X A CN 201180026946XA CN 201180026946 A CN201180026946 A CN 201180026946A CN 103068393 A CN103068393 A CN 103068393A
Authority
CN
China
Prior art keywords
formula
compound
ome
vii
iii
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201180026946XA
Other languages
English (en)
Chinese (zh)
Inventor
R·J·德赛
T-F·周
K·李
F·J·舍嫩
K·J·弗兰科夫斯基
J·奥贝
S·W·格里茨
H-J·周
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Gram Livre Biological Science Co Ltd
California Institute of Technology
University of Kansas
Original Assignee
Gram Livre Biological Science Co Ltd
California Institute of Technology
University of Kansas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gram Livre Biological Science Co Ltd, California Institute of Technology, University of Kansas filed Critical Gram Livre Biological Science Co Ltd
Publication of CN103068393A publication Critical patent/CN103068393A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/42—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving phosphatase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • C12Q1/485—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase involving kinase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
CN201180026946XA 2010-05-07 2011-05-06 用于抑制过渡型内质网atp酶的方法和组合物 Pending CN103068393A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US33266710P 2010-05-07 2010-05-07
US61/332,667 2010-05-07
PCT/US2011/035654 WO2011140527A2 (en) 2010-05-07 2011-05-06 Methods and compositions for inhibition of the transitional endoplasmic reticulum atpase

Publications (1)

Publication Number Publication Date
CN103068393A true CN103068393A (zh) 2013-04-24

Family

ID=44904519

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201180026946XA Pending CN103068393A (zh) 2010-05-07 2011-05-06 用于抑制过渡型内质网atp酶的方法和组合物

Country Status (8)

Country Link
US (1) US8865708B2 (https=)
EP (1) EP2566480A4 (https=)
JP (1) JP2013530942A (https=)
KR (1) KR20130128308A (https=)
CN (1) CN103068393A (https=)
AU (1) AU2011249859B2 (https=)
CA (1) CA2798698A1 (https=)
WO (1) WO2011140527A2 (https=)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8865708B2 (en) 2010-05-07 2014-10-21 California Institute Of Technology Methods and compositions for inhibition of the transitional endoplasmic reticulum ATPase
CN105828823A (zh) * 2013-10-18 2016-08-03 美国印第安纳大学研究和技术公司 乙型肝炎病毒组装效应物
CN106232595A (zh) * 2014-04-23 2016-12-14 巴斯夫欧洲公司 作为除草剂的二氨基三嗪化合物
CN106232586A (zh) * 2014-04-23 2016-12-14 巴斯夫欧洲公司 二氨基三嗪化合物及其作为除草剂的用途
CN106458996A (zh) * 2014-01-20 2017-02-22 克里弗生物科学公司 作为p97复合物的抑制剂的稠合嘧啶
CN106518849A (zh) * 2016-10-27 2017-03-22 上海人类基因组研究中心 喹唑啉类化合物及其制备方法和用途

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8906918B1 (en) * 2012-03-23 2014-12-09 University Of South Florida (A Florida Non-Profit Corporation) Compositions, methods of use, and methods of treatment
US9062026B2 (en) 2012-07-20 2015-06-23 Cleave Biosciences, Inc. Fused pyrimidines and substituted quinazolines as inhibitors of p97
CA2896731A1 (en) 2012-12-28 2014-07-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Inhibitors of the usp1/uaf1 deubiquitinase complex and uses thereof
US10479777B2 (en) 2013-07-16 2019-11-19 Basf Se Herbicidal azines
DE102013110714A1 (de) * 2013-09-27 2015-04-02 Eberhard Karls Universität Tübingen Medizinische Fakultät Prophylaxe und Behandlung einer nicht auf einer Proteinfaltungsstörung beruhenden neurodegenerativen Erkrankung
TW201605832A (zh) 2013-12-10 2016-02-16 克立弗生物科學公司 作為ｐ９７錯合物之抑制劑之單環嘧啶／吡啶化合物
CN106458937A (zh) 2014-04-11 2017-02-22 巴斯夫欧洲公司 作为除草剂的二氨基三嗪衍生物
AU2016249021A1 (en) 2015-04-17 2017-10-19 Assembly Biosciences, Inc. Hepatitis B viral assembly effectors
CN113727758A (zh) * 2019-03-01 2021-11-30 锐新医药公司 双环杂环基化合物及其用途
AU2023377192A1 (en) * 2022-11-07 2025-05-22 Kyoto University Nitrogen-containing heterocyclic compound

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006014420A1 (en) * 2004-07-06 2006-02-09 Angion Biomedica Corporation Quinazoline modulators of hepatocyte growth factor / c-met activity for the treatment of cancer
WO2007041282A2 (en) * 2005-09-29 2007-04-12 The Johns Hopkins University Methods and compositions for treatment of cystic fibrosis
WO2009011910A2 (en) * 2007-07-18 2009-01-22 Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Serices Imidazolidinone compounds, methods to inhibit deubiquitination and methods of treatment
US20090253717A1 (en) * 2008-01-17 2009-10-08 Brown Steven J Inhibitors of p97
WO2010003908A1 (en) * 2008-07-08 2010-01-14 Jakobsson, Andreas Screening assay for compounds targeting the p97 aaa-atpase complex in the ubiquitin proteasome system.

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ387292A3 (en) 1991-02-20 1994-04-13 Pfizer 2,4-diaminoquinazoline derivatives, process of their preparation and use as substances for increasing anti-tumorous activity
AU2002361846A1 (en) 2001-12-21 2003-07-15 Bayer Pharmaceuticals Corporation Quinazoline and quinoline derivative compounds as inhibitors of prolylpeptidase, inducers of apoptosis and cancer treatment agents
AU2003255482A1 (en) 2002-10-02 2004-04-23 Merck Patent Gmbh Use of 4 amino-quinazolines as anti cancer agents
WO2006105056A2 (en) * 2005-03-28 2006-10-05 Fmc Corporation Insecticidal 2,4-diaminoquinazolines and related derivatives
US20090209536A1 (en) * 2007-06-17 2009-08-20 Kalypsys, Inc. Aminoquinazoline cannabinoid receptor modulators for treatment of disease
US20100317607A1 (en) * 2007-06-27 2010-12-16 Infectious Disease Research Institute Use of compounds for preparing anti-tuberculosis agents
US8865708B2 (en) 2010-05-07 2014-10-21 California Institute Of Technology Methods and compositions for inhibition of the transitional endoplasmic reticulum ATPase

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006014420A1 (en) * 2004-07-06 2006-02-09 Angion Biomedica Corporation Quinazoline modulators of hepatocyte growth factor / c-met activity for the treatment of cancer
WO2007041282A2 (en) * 2005-09-29 2007-04-12 The Johns Hopkins University Methods and compositions for treatment of cystic fibrosis
WO2009011910A2 (en) * 2007-07-18 2009-01-22 Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Serices Imidazolidinone compounds, methods to inhibit deubiquitination and methods of treatment
US20090253717A1 (en) * 2008-01-17 2009-10-08 Brown Steven J Inhibitors of p97
WO2010003908A1 (en) * 2008-07-08 2010-01-14 Jakobsson, Andreas Screening assay for compounds targeting the p97 aaa-atpase complex in the ubiquitin proteasome system.

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8865708B2 (en) 2010-05-07 2014-10-21 California Institute Of Technology Methods and compositions for inhibition of the transitional endoplasmic reticulum ATPase
CN105828823A (zh) * 2013-10-18 2016-08-03 美国印第安纳大学研究和技术公司 乙型肝炎病毒组装效应物
CN105828823B (zh) * 2013-10-18 2019-06-14 美国印第安纳大学研究和技术公司 乙型肝炎病毒组装效应物
CN106458996A (zh) * 2014-01-20 2017-02-22 克里弗生物科学公司 作为p97复合物的抑制剂的稠合嘧啶
US10174005B2 (en) 2014-01-20 2019-01-08 Cleave Biosciences, Inc. Fused pyrimidines as inhibitors of p97 complex
CN106458996B (zh) * 2014-01-20 2020-11-03 克里弗生物科学公司 作为p97复合物的抑制剂的稠合嘧啶
CN106232595A (zh) * 2014-04-23 2016-12-14 巴斯夫欧洲公司 作为除草剂的二氨基三嗪化合物
CN106232586A (zh) * 2014-04-23 2016-12-14 巴斯夫欧洲公司 二氨基三嗪化合物及其作为除草剂的用途
CN106232595B (zh) * 2014-04-23 2020-01-14 巴斯夫欧洲公司 作为除草剂的二氨基三嗪化合物
CN106518849A (zh) * 2016-10-27 2017-03-22 上海人类基因组研究中心 喹唑啉类化合物及其制备方法和用途
CN106518849B (zh) * 2016-10-27 2019-08-16 上海人类基因组研究中心 喹唑啉类化合物及其制备方法和用途

Also Published As

Publication number Publication date
KR20130128308A (ko) 2013-11-26
CA2798698A1 (en) 2011-11-10
WO2011140527A3 (en) 2012-03-29
JP2013530942A (ja) 2013-08-01
AU2011249859B2 (en) 2014-07-03
EP2566480A2 (en) 2013-03-13
AU2011249859A1 (en) 2012-12-20
EP2566480A4 (en) 2014-03-19
WO2011140527A2 (en) 2011-11-10
US8865708B2 (en) 2014-10-21
US20110288082A1 (en) 2011-11-24

Similar Documents

Publication Publication Date Title
CN103068393A (zh) 用于抑制过渡型内质网atp酶的方法和组合物
JP4481344B2 (ja) クロマン置換ベンゾイミダゾール誘導体及び酸ポンプ阻害剤としてのそれらの使用
AU2016207168C1 (en) Quinazoline heterocyclic compound as EGFR kinase inhibitor, and preparation and application thereof
JP5391351B2 (ja) ヘテロ二環式メタロプロテアーゼ阻害薬
EP1827444B1 (en) Mnk1 or mnk2 inhibitors
JP5897566B2 (ja) 環式ｎ，ｎ’−ジアリールチオ尿素及びｎ，ｎ’−ジアリール尿素−アンドロゲン受容体アンタゴニスト、抗癌剤、その調製のための方法及び使用
CN101143845B (zh) 取代喹啉甲酰胍衍生物、其制备方法及其医药用途
EP3154982B1 (en) Compounds comprising 1,1',2,5'-tetrahydrospiro[indole-3,2'-pyrrole]-2,5'-dione system as inhibitors p53-mdm2 protein-protein interaction
CN101531638A (zh) 用作雌激素相关受体调节剂的化合物及其应用
WO2014079232A1 (zh) 7-氧代吡啶并嘧啶类化合物及其药用组合物和应用
CN111138358B (zh) Usp8抑制剂及其制备方法与应用
WO2018237007A1 (en) Inhibitors of phosphoinositide 3-kinase and histone deacetylase for treatment of cancer
CN113880772B (zh) 一类cdk激酶抑制剂及其应用
CN101289444B (zh) 一种嘧啶衍生物及其医药用途
CN100546980C (zh) 苯并咪唑衍生物:制备方法及医药应用
WO2011111675A1 (ja) 新規インドール誘導体
CN101500562B (zh) 噻吩并[3,2-c]吡啶-7-羧酸衍生物
WO2023061051A1 (zh) 一种磺酰胺类usp8抑制剂及其应用
EP3626712A2 (en) Liver x receptor (lxr) modulators
WO2004031180A1 (ja) キナゾリン−４−オン誘導体
Doddagaddavalli et al. Fluorenone–thiazolidine-4-one scaffolds as antidiabetic and antioxidant agents: design, synthesis, X-ray crystal structures, and binding and computational studies
EP3733186B1 (en) Novel dihydroquinazolinone compound or pharmacologically acceptable salt, and cell growth inhibitor
WO2020114519A1 (zh) 作为cdk-hdac双通路抑制剂的杂环化合物
CN111247137A (zh) 一种嘧啶类化合物、其制备方法及其医药用途
CN104177312B (zh) 一种含硒化合物及其医药用途

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
AD01 Patent right deemed abandoned

Effective date of abandoning: 20160217

C20 Patent right or utility model deemed to be abandoned or is abandoned